Yellow Fever Treatment Market Report Scope & Overview:

The Yellow Fever Treatment Market size is valued at USD 355.69 Million in 2025 and is projected to reach USD 587.07 Million by 2035, growing at a CAGR of 5.23% during the forecast period 2026–2035.

The Yellow Fever Treatment Market analysis report includes a thorough look at how the market works, new vaccines, and how they can be used to treat people. This is backed up by the growth of vaccination programs in areas where diseases are common, the growth of the market for traveller immunizations, the growth of the pipeline for recombinant thermostable vaccines, and the growth of health care infrastructure, which all help the market grow steadily from 2026 to 2035.

In 2025, more than 400 million doses of the Yellow Fever vaccine were given out around the world. This was because of large-scale immunization campaigns in Africa and South America and more people traveling from North America and Europe.

Market Size and Forecast:

• Market Size in 2025: USD 355.69 Million

• Market Size by 2035: USD 587.07 Million

• CAGR: 5.23% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get more information on Yellow Fever Treatment Market - Request Free Sample Report

Yellow Fever Treatment Market Trends:

• The 17D strain is still the main part of immunization programs and makes up most of the world's supply.

• The WHO, UNICEF, and government procurement agencies still push for massive immunization, mostly in Africa and South America.

• New ideas in the works aim to shorten the cold chain for distribution and make it easier to get to the most remote places.

• Monoclonal antibody therapies and experimental antiviral drugs are quickly becoming more common in the medical field.

• Antipyretics, PPIs, and H2 blockers are other important treatments during outbreaks that help with symptoms.

• More and more people are using immunization tracking systems and AI-based tools to predict outbreaks. This makes coverage and logistics better.

U.S. Yellow Fever Treatment Market Insights:

The Global Yellow Fever Treatment Market is expected to grow at a rate of 2.97% per year from USD 15.56 Million in 2025 to USD 20.25 Million by 2035. Growth is driven by more mass vaccination campaigns in areas where diseases are common, more people wanting to get vaccinated when they travel, more money going into research and development of recombinant and thermostable vaccines, and steady use of supportive care drugs in outbreak management.

Yellow Fever Treatment Market Growth Drivers:

• The Global Yellow Fever Treatment Market is growing quickly because more people are getting vaccinated.

This part talks about how the demand for traveller vaccinations is going up and how more money is going into next-generation vaccine technologies to help the industry grow. Governments, specialty clinics, and intensive care units are using more advanced methods to deal with outbreaks and improve patient outcomes. These include recombinant vaccines, thermostable formulations, and drugs that help patients. More work on antivirals and new ideas for digital immunization tracking and PPPs is speeding up the use of these tools and making the world better prepared for outbreaks.

By 2025, more than 62% of hospitals, specialty clinics, and government procurement agencies were expected to use advanced treatments for Yellow Fever.

Yellow Fever Treatment Market Restraints:

• There are a number of things that could slow the growth of the Global Yellow Fever Treatment Market, even though there is a lot of demand for it.

There are big problems that need to be solved, such as limited vaccine availability, problems with the cold chain, and problems with regulations. Dependence on live attenuated vaccines and slow acceptance of recombinant and inactivated vaccines have made it harder to diversify. Antiviral treatments are still being worked on, and it's not clear how well they will work or if they will be able to be sold. Supportive care drugs are very important, but they have become common and face competition from generic brands, which limits their potential for making money.

In 2025, more than 28% of vaccination campaigns in areas where the disease is common faced supply shortages or logistical problems.

Yellow Fever Treatment Market Opportunities:

• The Global Yellow Fever Treatment Market has a lot of room to grow because of new technologies, more money being spent on healthcare, and changing patient needs.

The recombinant and thermostable vaccines could be very helpful in keeping a cold chain, especially in places that are hard to reach. More research and development in antiviral and monoclonal antibody vaccines is a new way to fight outbreaks and serious infections. Digital health technology makes things work better. There is a positive growth trend because there is more demand for traveler vaccines in developed areas and immunization programs in Asia Pacific.

More than 35% of vaccine candidates in development in 2025 are recombinant and thermostable vaccines. This is a great chance to change the global Yellow Fever market.

Yellow Fever Treatment Market Segmentation Analysis:

• By Vaccines, Live-attenuated vaccines held the largest market share of 63.46% in 2025, while Recombinant vaccines are expected to grow at the fastest CAGR of 6.17% during 2026–2035.

• By Antiviral Therapeutics, Experimental antivirals dominated with 56.55% market share in 2025, whereas they are projected to record the fastest CAGR of 5.59% through 2026–2035.

• By Supportive Care Drugs, Antipyretics (fever management) accounted for the highest market share of 56.12% in 2025, while Proton Pump Inhibitors (GI protection) are expected to grow at the fastest CAGR of 3.64% during the forecast period.

• By Distribution Channel, Government Procurement Agencies dominated with a 54.72% share in 2025, while Hospital Pharmacies are anticipated to expand at the fastest CAGR of 4.49% through 2026–2035.

By Vaccines, Live‑attenuated vaccines Dominate While Recombinant Vaccines Grow Rapidly:

Live attenuated vaccines segment dominates the market made up a large part of the market because they are effective, provide long-term immunity, and are used in WHO's mass immunization campaigns in Africa and South America. In 2025, more than 280 million doses were used around the world. This shows that healthcare professionals and governments around the world prefer established vaccine technology.

The recombinant vaccines segment is likely to fastest growing because more money is being put into next-generation technologies, thermostable products, and making sure that immunocompromised people are safe. This part has become very popular, with 45 million doses given out in 2025, especially in areas where healthcare infrastructure is getting better.

By Antiviral Therapeutics, Experimental antivirals Dominate While it Grow Rapidly:

Experimental antivirals segment dominated the market in 2025, reflecting their critical role in ongoing clinical trials and outbreak management strategies. Despite limited commercialization, their strong presence in research pipelines and hospital‑based usage underscores their importance in shaping future treatment options.

Experimental antivirals are also projected to record the fastest growth, driven by increasing investments in antiviral R&D, rising demand for targeted therapies in severe Yellow Fever cases, and expanding collaborations between biotech firms and global health organizations. This dual dominance and rapid growth highlight their potential to transform the therapeutic landscape over the next decade.

By Supportive Care Drugs, Antipyretics (fever management) Dominate While Proton Pump Inhibitors (GI protection) Grow Rapidly:

Antipyretics (fever management) dominated the market in terms of market share in 2025, mainly due to its use in the management of fever and symptomatic treatment during Yellow Fever outbreaks. The prescriptions exceeded 120 million doses in total, showing the high degree of reliance on these established treatments in hospitals and clinics.

Proton Pump Inhibitors (GI protection) are expected to witness the fastest growth rate in the market due to its use in supportive care for the management of gastrointestinal complications in Yellow Fever patients. The usage has increased significantly, with more than 45 million doses administered in 2025.

By Distribution Channel, Government procurement agencies Dominates While Hospital Pharmacies Grow Rapidly:

Government procurement agencies segment dominated the Market, driven by large‑scale vaccine purchases for national immunization programs and outbreak response initiatives. Their bulk buying power and partnerships with WHO and UNICEF ensured widespread coverage across endemic regions, accounting for the majority of global distribution.

Hospital pharmacies are anticipated to expand at the fastest growth rate, supported by rising demand for traveller vaccinations, increased hospital‑based outbreak management, and growing adoption of supportive care drugs. In 2025, hospital pharmacies recorded a sharp rise in vaccine and therapeutic dispensing, reflecting their growing role in both preventive and acute care delivery.

Yellow Fever Treatment Market Regional Analysis:

Middle East and Africa Yellow Fever Treatment Market Insights:

In 2025, the Middle East and Africa market will have the biggest share of the global market, at 44.31%. This is because of the high rates of outbreaks and the large vaccination programs run by WHO, UNICEF, and governments. Government procurement organizations are the main way that vaccines are distributed. This means that more people in both rural and urban areas can get them.

Africa is the center of the vaccine market, with Nigeria, Ghana, and the Democratic Republic of Congo being some of the biggest buyers. Investments in research and development of thermostable vaccines, digital immunization tracking, and partnerships are expected to help the market grow.

Get Customized Report as per Your Business Requirement - Enquiry Now

Ghana Yellow Fever Treatment Market Insights

Ghana is one of Africa's most dynamic markets. Because of disease outbreaks, government vaccination efforts, and WHO-supported vaccination programs, the market is always in need of new solutions. It is putting money into research and development, especially in recombinant and thermostable technology, to be more prepared and less reliant on imports. It is also putting money into new hospitals, digital immunization tracking, and partnerships between the public and private sectors to make its position in the area even stronger.

Asia-Pacific Yellow Fever Treatment Market Insights:

The Asia Pacific Yellow Fever Treatment Market is growing the fastest, and it is expected to grow at a rate of 6.65% per year from 2026 to 2035. The market is growing because more people need vaccines for travelers, healthcare infrastructure, and diseases that are spread by mosquitoes. Governments in India, China, and Southeast Asia are putting a lot of money into vaccination programs, and there are new developments in recombinant and thermostable vaccines that are gaining ground. The Asia Pacific region has an advantage in shaping the future market because of its strategic partnerships with WHO and other groups.

China Yellow Fever Treatment Market Insights:

China is one of the most dynamic markets in Asia Pacific. This is because healthcare is modernizing quickly, more people are traveling abroad, and the government is strongly committed to preventing infectious diseases. To reduce its reliance on imports and build its own supply chain capabilities, China is putting money into the development of vaccines like recombinant and thermostable vaccines.

Latin America Yellow Fever Treatment Market Insights:

Latin America Bio Manguinhos (Fiocruz) leads the way in vaccine production and distribution in Latin America. Government immunization programs that are common, partnerships with the WHO, and a lot of participation from the public sector all help growth. More outbreaks in Brazil and other nearby countries, along with better healthcare infrastructure, are driving up demand in the region. Latin America's global presence grows when it forms strategic partnerships with African countries to supply vaccines.

North America Yellow Fever Treatment Market Insights:

The North America yellow fever treatment market is growing because a lot of people get vaccinated when they travel, the medical infrastructure is very good, and a lot of people in the US and Canada take supportive care medications. Government procurement programs, hospital pharmacies, and clinics are the main places where yellow fever vaccines are given out. Traveler awareness and ongoing improvements in recombinant and thermostable vaccine technologies are also important factors in the market. Reimbursement policies and the knowledge of medical professionals are also important parts of the very advanced market.

U.S. Yellow Fever Treatment Market Insights:

The U.S. Yellow Fever Treatment Market is growing because many travelers get vaccinated, hospitals are good at responding to outbreaks, and many people are using supportive care medications. The U.S. is still a major market in North America because of more money going into the development of recombinant vaccines, more specialty clinics, and a more advanced system for tracking immunizations.

Europe Yellow Fever Treatment Market Insights:

Europe Yellow Fever Treatment Market, which is driven by a strong demand for vaccinations among travelers, along with a well-developed healthcare infrastructure and a strong base of supportive care medications. Stringent vaccination policies are implemented by all governments in Europe, which require travelers to be vaccinated if they are traveling to endemic regions. This has ensured a steady growth rate in the region. There has been a lot of innovation in recombinant and thermostable vaccines, which has improved accessibility.

Germany Yellow Fever Treatment Market Insights:

Germany is one of the biggest markets in Europe because a lot of people travel there, the hospital system is well-developed, and the government requires travelers to endemic areas to get vaccinated. To build domestic capabilities and reduce reliance on imports, there are investments in the development of next-generation vaccines, such as recombinant and thermostable vaccines. Hospital pharmacies are important for giving vaccines, but medications for supportive care are already well known for how to respond to an outbreak.

Yellow Fever Treatment Market Competitive Landscape:

Sanofi Pasteur SA is a French multinational pharmaceutical company that is a leader in the development of vaccines. It is also the world leader in the market for "Yellow Fever Vaccines," especially the live attenuated form of the 17D strain, which is the main basis for WHO immunization programs against the disease. Sanofi Pasteur is the market leader because it can make a lot of products at once, works well with international health organizations, and has a strong distribution network in countries where the disease is common.

• Sanofi Pasteur, a leading developer of vaccines, announced the expansion of its vaccine production unit in Lyon, France, in September 2025, to increase the supply of vaccines to counter outbreaks and immunization programs globally.

Bio Manguinhos is a public sector company that makes vaccines and is a major player in the South American vaccine industry. It provides most of the continent's Yellow Fever vaccine needs. It is a big part of the vaccination campaigns that the WHO and PAHO run, especially in areas where the disease is common. It is a major player in the Latin American vaccine industry because it knows how to make vaccines and works with the government.  

• Bio Manguinhos announced in July 2025 that it had formed an alliance with the WHO to distribute vaccines in Africa.

GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company that is becoming more important in the Yellow Fever vaccine market. The company focuses on creating recombinant and next-generation vaccine technologies. The company's strong research and development pipeline and worldwide distribution network make it a key player in the effort to move beyond traditional live attenuated vaccine technologies.

• In November 2025, GlaxoSmithKline announced the success of its recombinant vaccine candidate for the treatment and prevention of Yellow Fever in Phase II.

Yellow Fever Treatment Market Key Players:

Some of the Yellow Fever Treatment Market Companies are: 

• Sanofi Pasteur SA

• Bio-Manguinhos (Fiocruz, Brazil)

• GlaxoSmithKline plc (GSK)

• Pfizer Inc.

• Johnson & Johnson Services Inc. (Janssen)

• Takeda Pharmaceutical Company Ltd.

• Bayer AG

• BioCryst Pharmaceuticals Inc.

• Tychan Pte. Ltd.

• Emergent BioSolutions Inc.

• Novartis AG

• Merck & Co. Inc.

• AbbVie Inc.

• CSL Limited (Seqirus)

• Moderna Inc.

• AstraZeneca plc

• Roche Holding AG

• Serum Institute of India

• Indian Immunologicals Ltd.

• Panacea Biotec Ltd.